CALC Overview

CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

CalciMedica Inc revenue for the last quarter amounts to -4.38M USD, decreased -28.95

CalciMedica Inc. EPS for the last quarter amounts to -4858000.00 USD, decreased -2.33

CalciMedica Inc (CALC) has 16 emplpoyees as of March 11 2026.

Today CALC has the market capitalization of 10.63M USD.